Autonomic Dysfunction, Orthostatic Intolerance
Conditions
Keywords
Blood Pressure, Hemodynamics, Non-invasive, Continuous, Autonomic Function Testing
Brief summary
Background: The investigational device, "Task Force® CORE" (TFC, CNSystems Medizintechnik GmbH, Graz, Austria) together with the "Task Force® CARDIO" (TFCARDIO, CNSystems Medizintechnik GmbH, Graz, Austria) medical device software, is a new CE-marked medical device for continuous non-invasive determination of blood pressure (BP), cardiac output (CO) and derived parameters based on the well established CNAP® (continuous non-invasive arterial pressure) technology by CNSystems. Aim: The primary aim of this prospective, method comparison, open study is data acquisition for the performance evaluation of the TFC during autonomic function testing in comparison with an clinically accepted reference method. Setting: The setting of the clinical investigation will be the autonomic function testing laboratory at the Department of Neurology, the University Hospital Center Zagreb. Inclusion criteria: Patients who are over 18 years and who provide written informed consent. Sample size: The study has an calculated sample size of 70 patients. Considering a drop-out rate of 5%, a total of 75 patients will be included. Statistics: Descriptive statistics, values for the percentage error and correlation estimates will be derived. Furthermore, scatterplot, Bland-Altman analysis, concordance analysis of parameter changes and further comparative statistics will be performed.
Interventions
DIAGNOSTIC_TESTAutonomic Function Testing
Autonomic Function Testing (AFT) includes Valsalva Manoever, Deep Breathing Test, and Head-up Tilt Table Testing.
Sponsors
CNSystems Medizintechnik GmbH
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients (patients aged ≥ 18 years) * Patients giving written informed consent to participate in the study. * Patients with intact perfusion of both hands evidenced by a positive Allen's test. * Patients with orthostatic intolerance will be included
Exclusion criteria
* Patients with vascular implants at the sites of non-invasive BP measurement (fingers or upper arms) * Very low perfusion in the periphery * Arterial vascular diseases (arteriosclerosis, Raynaud's syndrome, endarteritis obliterans, collagenosis, severely advanced vascular diseases (PAOD)) * Patients with significant edema in the fingers * Patients with atrial fibrillation * Patients with valvular disease of grade 2 or above * Patients with ventricular assist devices * Subjects not passing the Allen's test for both hands. * Patients with a large lateral difference in BP (\> 15 mmHg for systolic BP and/or \>10 mmHg for diastolic BP) or with same arm measurement differences \> 10 mmHg in systolic or diastolic BP during assessment of lateral differences
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Agreement of blood pressure between investigational and reference device. | The agreement is calculated for the 5 minutes supine baseline period | The agreement of blood pressure variables \[systolic, diastolic and mean pressure in mmHg \[millimetres of mercury)\] between both devices will be assessed by means of Scatterplot and Bland-Altman analysis. |
| Agreement of heart rate between investigational and reference device. | The agreement is calculated for the 5 minutes supine baseline period | The agreement of heart rate (bpm \[beats per minute)\] between both devices will be assessed by means of Scatterplot and Bland-Altman analysis. |
| Agreement of cardiac output between investigational and reference device. | The agreement is calculated for the 5 minutes supine baseline period | The agreement of cardiac output (in l/min) between both devices will be assessed by means of Scatterplot and Bland-Altman analysis. |
Contacts
CONTACTChief Technology Officer
Outcome results
None listed